Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EVasion

Financiado

Evasion of antitumor immunity and immunotherapy by melanoma extracellular vesicl...

Evasion of antitumor immunity and immunotherapy by melanoma extracellular vesicles Melanoma is the deadliest of the skin cancers. Immune checkpoint inhibitors (ICI), which are blocking antibodies that help to restore antitumor immunity, are currently used for the treatment of metastatic melanoma. However, only a... ver más

31/05/2025

FUNDACAO CHAMPALIM...

173K€

Presupuesto del proyecto: 173K€

Líder del proyecto

FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR.... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-05-03

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100%

1 Participantes

FUNDACAO CHAMPALIMAUD

172.62K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2015-69169-R LAS CELULAS NATURAL KILLER Y LAS NANOVESICULAS EXTRACELULARE... 169K€ Cerrado

PTQ-11-04779 Potenciación de la antigenicidad tumoral por inhibición diri... 90K€ Cerrado

PCIN-2016-025 NANOVACUNAS DISEÑADAS PARA INMUNOTERAPIA ANTITUMORAL 100K€ Cerrado

PID2021-124010OB-I00 FARMACOS MULTI-DIANA EN LA INMUNOTERAPIA DEL CANCER: DESCUBR... 145K€ Cerrado

SAF2014-53563-REDT RED DE INMUNOTERAPIA DEL CANCER 32K€ Cerrado

PID2021-128206NB-I00 MODELANDO LA CARCINOGENESIS CON CELULAS PLUTIPOTENTES PARA E... 200K€ Cerrado

Duración del proyecto: 24 meses Fecha Inicio: 2023-05-03
Fecha Fin: 2025-05-31

Líder del proyecto

FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR.... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 173K€

Descripción del proyecto Melanoma is the deadliest of the skin cancers. Immune checkpoint inhibitors (ICI), which are blocking antibodies that help to restore antitumor immunity, are currently used for the treatment of metastatic melanoma. However, only approximately 20% of the patients respond to ICI. Understanding the molecular mechanisms behind the resistance to these therapies is essential to predict patients' response and increase treatment success. Extracellular vesicles(EVs), nanosized structures released by virtually all cells, are key mediators of cell-cell communication and horizontal transfer of biomolecules locally and systemically. EVs are known to play an important role in cancer biology by regulating cell apoptosis, angiogenesis, antigen presentation and immune modulation. In recent years, EVs have been shown to also act as protein-decoys, through binding and sequestering soluble proteins, thus preventing protein-target interactions. Previous work from the host group shows that EVs excreted by melanoma cell lines express interferon-γ receptor (IFNGR). Thus, we hypothesize that melanoma-derived EVs modulate the bioavailability and activity of this cytokine. Preliminary results show that EVs isolated from mouse metastatic melanoma B16-F10 cells express IFNGR, bind to IFNγ, and protect tumor cells from the cytotoxic effect of IFNγ. Because resistance to antitumor immunity and to ICI has been linked to defects in IFNγ signaling, this project aims to investigate whether IFNGR+ EVs downregulate IFNγ signaling and ICI response. This research has the potential to unveil a novel yet overlooked cancer immune evasion mechanism mediated by IFNGR+ EVs, which may provide crucial insights to optimize current cancer therapies and ultimately improve patient outcomes.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores